Disease Domain | Count |
---|---|
Neoplasms | 7 |
Infectious Diseases | 5 |
Nervous System Diseases | 2 |
Hemic and Lymphatic Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 12 |
Synthetic peptide | 2 |
Chemical drugs | 1 |
Recombinant polypeptide | 1 |
Fusion protein | 1 |
Target |
Mechanism HDAC inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PfHDAC1 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism JAK2 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Jul 2024 |
Sponsor / Collaborator |
Start Date16 Oct 2019 |
Sponsor / Collaborator |
Start Date01 Mar 2013 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Secondary Amine Pendant β-Peptide Polymers | Wound Infection More | Preclinical |
CD73 inhibitors(East China University of Science & Technology) ( CD73 ) | Neoplasms More | Preclinical |
WWQ-131 ( JAK2 ) | Myeloproliferative Disorders More | Preclinical |
DWP-0016 ( HDACs x p53 ) | Neoplasms More | Preclinical |
PI3K/AKT/GSK3β modulators(East China University of Science & Technology) ( Akt x GSK-3β x PI3Ks ) | Heart Failure More | Preclinical |